There is no known antidote for overdoses of gemcitabine HCl. Myelosuppression, paresthesias, and severe rash were the principal toxicities seen when a single dose as high as 5.7 g/m2 was administered by I.V. infusion over 30 minutes every 2 weeks to several patients in a Phase 1 study. In the event of suspected overdose, the patient should be monitored with appropriate blood counts and should receive supportive therapy, as necessary.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
